2016年1月5日
Messenger RNA delivery of a cartilage-anabolic transcription factor as a disease-modifying strategy for osteoarthritis treatment.
Scientific reports
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 6
- 号
- 開始ページ
- 18743
- 終了ページ
- 18743
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1038/srep18743
- 出版者・発行元
- NATURE PUBLISHING GROUP
Osteoarthritis (OA) is a chronic degenerative joint disease and a major health problem in the elderly population. No disease-modifying osteoarthritis drug (DMOAD) has been made available for clinical use. Here we present a disease-modifying strategy for OA, focusing on messenger RNA (mRNA) delivery of a therapeutic transcription factor using polyethylene glycol (PEG)-polyamino acid block copolymer-based polyplex nanomicelles. When polyplex nanomicelles carrying the cartilage-anabolic, runt-related transcription factor (RUNX) 1 mRNA were injected into mouse OA knee joints, OA progression was significantly suppressed compared with the non-treatment control. Expressions of cartilage-anabolic markers and proliferation were augmented in articular chondrocytes of the RUNX1-injected knees. Thus, this study provides a proof of concept of the treatment of degenerative diseases such as OA by the in situ mRNA delivery of therapeutic transcription factors; the presented approach will directly connect basic findings on disease-protective or tissue-regenerating factors to disease treatment.
- リンク情報
-
- DOI
- https://doi.org/10.1038/srep18743
- PubMed
- https://www.ncbi.nlm.nih.gov/pubmed/26728350
- PubMed Central
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700530
- Web of Science
- https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000368355700001&DestApp=WOS_CPL
- ID情報
-
- DOI : 10.1038/srep18743
- ISSN : 2045-2322
- PubMed ID : 26728350
- PubMed Central 記事ID : PMC4700530
- Web of Science ID : WOS:000368355700001